Company intelligence / Profile preview
Chengdu First Pharmaceutical
Chengdu, Sichuan, Chinacddyyy.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has developed small molecule drugs, with a focus on infectious and nervous system diseases. It has conducted at least two clinical trials, including a completed bioequivalence study comparing its oseltamivir phosphate granules to TAMIFLU® in healthy subjects. Some products have achieved regulatory approval outside China as early as December 1989 in Canada.
- Therapeutic areas
- OncologyEndocrinologyImmunologyHematologyNeurologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Chengdu First Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu First Pharmaceutical.